Last reviewed · How we verify

Dexamethasone 10 mg

Thomas L Bradbury · FDA-approved active Small molecule Quality 2/100

Dexamethasone 10 mg is a Small molecule drug developed by Thomas L Bradbury. It is currently FDA-approved. Also known as: Decadron.

Dexamethasone 10 mg, marketed by Thomas L Bradbury, is a well-established corticosteroid with a broad therapeutic profile. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in generic competition following the patent expiry.

At a glance

Generic nameDexamethasone 10 mg
Also known asDecadron
SponsorThomas L Bradbury
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexamethasone 10 mg

What is Dexamethasone 10 mg?

Dexamethasone 10 mg is a Small molecule drug developed by Thomas L Bradbury.

Who makes Dexamethasone 10 mg?

Dexamethasone 10 mg is developed and marketed by Thomas L Bradbury (see full Thomas L Bradbury pipeline at /company/thomas-l-bradbury).

Is Dexamethasone 10 mg also known as anything else?

Dexamethasone 10 mg is also known as Decadron.

What development phase is Dexamethasone 10 mg in?

Dexamethasone 10 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing